The Clinical Research Program at the Cardiovascular Institute allows our physicians to participate in national studies which provide current data to enhance treatment protocols for cardiovascular issues.

Of course, we could not participate without our patients who volunteer to be a part of a clinical trial or registry. Through our participation, select patients may have access to new technologies or medical therapies that are not yet widely available. However, many studies are simply observational and collect data on how patients respond to various therapies that are already the standard of care, to determine where improvements may be needed.  No matter what type of research, it is our patients participation that provides the necessary data to make improvements in cardiovascular treatment.

 

The selection criteria for each study are very specific.

Most patients will not be asked to participate in research.  Patients who are considered a good candidate for a certain study, and are approached about participating, are under no obligation to enroll.  Your cardiologist and our research coordinator will provide you with comprehensive information to make an informed decision on your study participation and treatment options.  Patients who participate in studies are monitored, most commonly through follow-up appointments, for a prescribed amount of time per the study requirements.  Patients are asked to please consider their long term commitment to attend all follow-up appointments as part of their participation.  While patients can certainly choose to remove themselves from a study, it is our hope that those who choose to enroll will work with us to complete their participation.

At Cardiovascular Institute, we believe that our participation in clinical research gives us access to new data and information that continually improves the quality of care we provide to all of our patients.  We’re proud to bring this level of commitment to treating cardiovascular disease to our community.

If  you have any questions regarding your eligibility for studies that Cardiovascular Institute is currently participating in you may contact our study coordinator:

Sara Hobbs at (850)769-0329.

 

Links to trials actively enrolling at Cardiovascular Institute of Northwest Florida

CREST 2

CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL

In addition, to view a short video explanation of the objectives of this trial and to learn who may be a candidate visit crest2trial.org

Principal Investigator:  Amir Haghighat, M.D.


CREST-2 REGISTRY 

The objective of C2R is to promote the rapid initiation and completion of enrollment in the CREST-2 randomized clinical trial (clinicaltrials.gov ID NCT02089217). Patients with severe symptomatic and asymptomatic carotid artery occlusive disease will be treated with carotid artery stenting (CAS) performed by experienced and skilled interventionists. Interventionists’ eligibility will be determined by a multi-specialty Interventional Management Committee (IMC). Patient eligibility will include patients with standard or high-risk, symptomatic or asymptomatic carotid artery disease. Patients will be followed for the occurrence of post-procedural complications. The primary safety and quality endpoint will be the occurrence of any stroke or death within the 30-day period following the stenting procedure.

https://clinicaltrials.gov/ct2/show/NCT02240862?term=crest+2&draw=2&rank=1

Principal Investigator:  Amir Haghighat, M.D.

Links to trials Cardiovascular Institute continues to monitor

Pioneer III

The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents. https://clinicaltrials.gov/ct2/show/NCT03168776?term=Pioneer+III&draw=2&rank=1

 

ADAPTResponse

The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

https://clinicaltrials.gov/ct2/show/NCT02205359?term=ADAPTResponse&rank=1

 

CONNECT-HF

A large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multifaceted, health system-level quality-improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics. https://clinicaltrials.gov/ct2/show/NCT03035474?term=connect+hf&draw=2&rank=1